Articles related to PHARMACOTHERAPY

A network meta-analysis of 15 randomized trials found that no pharmacologic treatment outperformed placebo for MS-related fatigue severity, though amantadine and fampridine showed statistically significant and potentially clinically meaningful improvements in fatigue-related daily functioning.

Post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials found that oral orforglipron at maximum dose produced significant weight reductions across all menopausal stages in women with obesity, with and without type 2 diabetes, at 72 weeks.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

The FDA approved baxdrostat (Baxfendy), a selective oral aldosterone synthase inhibitor, as an adjunctive treatment for adults with hypertension uncontrolled on at least two existing antihypertensive agents, including a diuretic.